Skip to main content

Table 2 Distribution of Kidney Lesion Subtype for A/J and C57BL/6 Tsc2+/- Cohorts

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

  % of Total Score per Kidney
Tsc2+/-Cohort (strain, treatment, age) Cyst Pre-papillary Papillary Solid
C57BL/6, untreated, 9 months 13.34 26.67 45.88 14.11
C57BL/6, untreated, 12 months 8.64 34.15 43.21 8.64
A/J, untreated, 3 months 11.54 19.23 57.69 11.54
A/J, untreated, 5 months 9.47 21.59 62.12 6.82
A/J, untreated, 7 months 4.98 23.6 60.17 11.26
A/J, untreated, 9 months 12.38 21.27 53.63 12.51
A/J, untreated, 12 months 11.18 16.75 59.07 13.52
Group 1
A/J rapa daily × 4 weeks then weekly × 8 weeks
31.4 51.44 14.83 0.87
Group 2
A/J rapa daily × 4 weeks
18.08 58.67 22.64 0.91
Group 3
A/J rapa weekly × 12 weeks
20.88 65.86 13.02 0.25